First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma(CheckMate 743):a multicentre,randomised,open-label,phase 3 trial[J]. Lancet,2021,397(10272):375-386. PART 02证据水平1b。PART 03研究背景 恶性...
恶性胸膜间皮瘤(malignant pleural mesothelioma, MPM)起病隐匿,只有少数患者符合手术治疗的条件,大部分 MPM 患者在确诊时已处于疾病的晚期。 恶性胸膜间皮瘤治疗选择十分有限,过去15余年,新药研究进展缓慢,长期停滞在以培美曲塞铂类化疗为...
恶性胸膜间皮瘤(malignant pleural mesothelioma, MPM)起病隐匿,只有少数患者符合手术治疗的条件,大部分 MPM 患者在确诊时已处于疾病的晚期。 恶性胸膜间皮瘤治疗选择十分有限,过去15余年,新药研究进展缓慢,长期停滞在以培美曲塞铂类化疗为主的传统治疗模式。晚期患者中位总生存时间(OS)约为1年,5年生存率不到10%[2...
恶性胸膜间皮瘤(malignant pleural mesothelioma,MPM)是一种起源于胸膜间皮细胞的高度侵袭性恶性肿瘤,临床上较为罕见。自2004年培美曲塞联合顺铂获批一线治疗以来,10余年来没有任何新的系统性治疗手段获批。2020年世界肺癌大会(WCLC)线上主席研讨会上,CheckMate-743研究[1]结果正式发布,首次证实与标准化疗相比,纳武利尤...
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial - ScienceDirectBackground Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have ...
Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。
Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.
Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. [Crossref] [PubMed] ...
Checkmate 743–previously untreated unresectable malignant pleural mesothelioma, in combination with YERVOY; Checkmate 037–previously treated metastatic melanoma; Checkmate 066-previously untreated metastatic melanoma; Checkmate 067–previously untreated metastatic melanoma, as a single agent or in...
目的:在 临床试验CheckMate 743 (NCT02899299) 中,nivolumab(纳武利尤单抗)+ipilimumab(伊匹木单抗)显著延长了不可切除的恶性胸膜间皮瘤 (malignant pleural mesothelioma,MPM) 患者的总生存期。我们报道了患者报告结局(patient-reported ou...